Ubs Group Ag Windtree Therapeutics Inc Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.3 - $306.0 $9,750 - $9.95 Million	-32,500 Reduced 98.88%	367 $0
Q2 2022 Aug 10, 2022	BUY	$0.38 - $1.14 $10,984 - $32,952	28,906 Added 729.77%	32,867 $14,000
Q1 2022 May 16, 2022	BUY	$0.94 - $1.6 $43 - $73	46 Added 1.17%	3,961 $4,000
Q4 2021 Feb 14, 2022	BUY	$1.4 - $2.31 $3,553 - $5,862	2,538 Added 184.31%	3,915 $7,000
Q3 2021 Nov 15, 2021	SELL	$1.66 - $2.27 $11,361 - $15,535	-6,844 Reduced 83.25%	1,377 $3,000
Q2 2021 Aug 13, 2021	BUY	$1.68 - $2.79 $11,754 - $19,521	6,997 Added 571.65%	8,221 $19,000
Q1 2021 May 12, 2021	BUY	$2.14 - $6.18 $1,833 - $5,296	857 Added 233.51%	1,224 $3,000
Q4 2020 Feb 11, 2021	SELL	$4.98 - $7.47 $8,316 - $12,474	-1,670 Reduced 81.98%	367 $2,000
Q3 2020 Nov 12, 2020	SELL	$5.5 - $9.9 $8,035 - $14,463	-1,461 Reduced 41.77%	2,037 $11,000
Q2 2020 Jul 31, 2020	BUY	$3.3 - $9.96 $11,543 - $34,840	3,498 New	3,498 $25,000

4.09K

Ticker WINT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,627,900
Market Cap $34M
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.